Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NET-02 second-line therapy trial in progressive poorly differentiated extrapulmonary neuroendocrine carcinoma
ISRCTN10996604Phase 2Completed
- Sponsor
- The Christie
- Start
- Oct 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial in extrapulmonary neuroendocrine carcinoma (EPNEC) comparing nal-IRI + fluorouracil + folinic acid with docetaxel (2 arms). Primary endpoint: Progression-free survival rate at 6 months. Started Oct 2018; status: completed.
02
Drugs
nanoliposomal irinotecanfluorouracilfolinic aciddocetaxel
03
Conditions
extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on ISRCTN10996604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10996604.